Savsu to supply Novartis’ newly-approved SMA treatment

By Vassia Barba

- Last updated on GMT

(Image: Getty/ClaireMcAdams
(Image: Getty/ClaireMcAdams

Related tags: Novartis, Savsu Technologies, AveXis, Zolgensma

Novartis to continue with AveXis’ adoption of Savsu’s evo cold chain management technology for newly-approved gene therapy.

Savsu Technologies, a New Mexico, US-based company, which creates temperature controlled systems and transport containers developed the evo Cold Chain 2.0 system especially for cell and gene therapies shipments.

Evo ‘smart shippers’ of the Cold Chain 2.0 system were designed to offer thermal stability and to have integrated sensor and communication systems. The containers are connected with evo.is, a cold chain cloud application providing real-time data whilst in transit.

The technology was adopted by AveXis, the developer of Zolgensma (onasemnogene abeparvovec-xioi), which is the first one-time gene therapy for the treatment of spinal muscular atrophy (SMA) in children less than two years old.

Novartis acquired AveXis​ in April 2018 for $8.7bn (€7.79bn) and led Zolgensma to receive approval​ from the US Food and Drug Administration (FDA) last month.

Currently, 44% of Savsu’s shares are owned by Biolife Solutions, which also has an exclusive option to purchase all remaining shares.

Mike Rice, CEO of BioLife, commented on the partnership with Savsu, saying that the company looks forward to additional announcements related to new Savsu customers.

Related news

Show more

Related products

show more

Connectivity & Integration in Biomanufacturing

Connectivity & Integration in Biomanufacturing

Wheeler Bio | 17-Nov-2022 | Technical / White Paper

As the Pharma 4.0 initiative sets a new industry paradigm, more biomanufacturing companies are asking how they can design and build facilities that apply...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us

Products

View more

Webinars